Study and Monitoring of Multiple Endocrine Neoplasia Type 1

Launched by CENTRE HOSPITALIER UNIVERSITAIRE DIJON · May 24, 2019

Keywords

ClinConnect Summary

This clinical trial, called the Study and Monitoring of Multiple Endocrine Neoplasia Type 1 (MEN1), is looking into a rare genetic condition that can lead to the growth of tumors in glands that produce hormones, particularly in the parathyroid, pituitary gland, and pancreas. Understanding this condition better is important because it can help doctors provide the right treatments, identify other potential tumors early, and guide family members who might be at risk. The trial aims to gather information from a larger group of patients to improve how MEN1 is diagnosed and managed.

To participate in the trial, patients must have symptoms related to MEN1, such as having at least two types of tumors or a known tumor linked to the MEN1 gene. Children can join if their parents agree. There is also a group for patients who don’t have symptoms but carry the MEN1 gene mutation. Participants can expect to be monitored closely and have their health managed as part of the study. This trial is currently recruiting patients of all ages and genders, and it aims to provide valuable insights that could enhance the understanding and treatment of MEN1.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • SYMPTOMATIC PATIENTS
• • person (adult or minor) who has not opposed participation
• • if the patient is a minor, the parents must not oppose their child's participation,
• • at least two of the three main types of lesions (parathyroid, pancreas, pituitary gland)
• • OR a known isolated tumor, main type or not, associated with the gene mutation of the NEM1 locus on chromosome 11q13
• • OR an isolated tumor, main type or not, in an individual with a confirmed family history of NEM1
• • ASYMPTOMATIC PATIENTS WITH A MUTATION
• • - Presence of a characteristic mutation of NEM1
• • Exclusion Criteria: NA